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Summary Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic
melanoma. CBIO-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its
corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts
and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared
to dacarbazine. Pharmacokinetic studies were performed with CBIO-277 in mice treated i.v. at the LDIO
(750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time
curve (AUC) was 142 mM x minutes). Drug metabolism occurred as evidenced by the HPLC identification of
the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites.
A Phase I trial using a short infusion with doses repeated every 21 days has been performed. Thirty-six
patients received 80 courses over a dose range of 80-6,000 mg m-2. The dose limiting toxicity was nausea and
vomiting which occurred in 80% of the evaluable courses > 900 mg m-2. The only other common side effect
was a flushing or warm sensation, which occurred in over 75% of courses at > 1,350 mg m-2. There were no
hemodynamic consequences. Responses occurred in patients with melanoma (one complete, two partial, one
mixed/I 1), sarcoma (one mixed/6) and carcinoid (one partial/i). Pharmacokinetics were performed in 46
courses. The CB10-277 AUC increased linearly with dose (r = 0.9203, P<0.001) up to 700 mM x minutes at
6,000 mg m-2). Evidence of CBIO-277 metabolism was observed, as in mice, by detection of the monomethyl
species and other metabolites. However, the plasma levels of the monomethyl species in patients (1.8 and
3.7 mM x minutes at 6,000 mg m-2) were less than those predicted from studies in mice. Despite this,
antitumour activity in dacarbazine sensitive histologies was observed and additional studies with CB10-277 are
recommended.
The antitumour activity of triazenes was first observed in
animal tumours at the Southern Research Institute during
development of inhibitors of nucleic acid synthesis (Shealy et
al., 1962). The basic triazene structure is shown in Figure 1.
Compounds with different R, substitutents in position at N'
(Loo & Lin, 1972; Audette et al., 1973; Connors et al., 1976;
Loo et al., 1976; Giraldi et al., 1977; Hatheway et al., 1978;
Wilman & Coddard, 1980; Gescher et al., 1981) and R2 and
R3 substituents at N3 (Audette et al., 1973; Connors et al.,
1976; Hatheway et al., 1978; Wilman & Goddard, 1980;
Gescher et al., 1981; Shealy & Krauth, 1966; Vaughn et al.,
1984) have been studied by various groups for activity in
animal tumours. While a range of structural variations at RI
can be tolerated, it is generally accepted that at least one
methyl group is required at either R2 or R3 in order to allow
the formation of a monomethyl species for antitumour
activity (Audette et al., 1973).
Dimethyltriazenoimidazolecarboxamide (dacarbazine, Figure
2a) has reproducible antitumour activity in patients with
lymphoma, sarcomas, and melanomas (Beretta et al., 1976)
and is frequently used in the treatment of patients with
recurrent melanoma because there are few chemotherapeutic
alternatives. Dacarbazine undergoes in vitro decomposition in
aqueous solution at physiologic pH (Shealy & Krauth, 1966).
These decomposition products are not thought to contribute
to in vivo antitumour activity (Julliard & Vernin, 1981).
However, in vivo metabolite activation of dacarbazine by
N-demethylation (as shown in Figure 2) is thought to be
required for antitumour activity (Bono, 1976). The hydroxy-
methyl (Figure 2b) and the monomethyl (Figure 2c) inter-
mediates formed during in vivo activation are chemically
unstable and heat labile. Either the monomethyl species, or
the methyl carbonium ion formed from it, is capable of
methylating DNA (Julliard & Vernin, 1981). However,
methylation of DNA is not the sole determinant of cytotox-
icity. In a cell line deficient in repairing DNA alkylations at
the 06 position of guanine (Mer-) the hydroxymethyl and
the monomethyl species (Figure 2B, C respectively) showed
greater antitumour activity than the parent compound (Gib-
son et al., 1986). In contrast, in a cell line capable of 06
guanine alkylation repair (Mer+) the three compounds were
equitoxic.
1-(4-carboxyphenyl)-3,3-dimethyltriazene (CBIO-277, Figure
2a) is a dacarbazine analog which is soluble and stable in
aqueous solution at physiologic pH (Wilman & Goddard,
1980). CBIO-277 required metabolic activation, similar to
that of dacarbazine (Figure 2), for antitumour activity (Con-
nors et al., 1976; Julliard & Vernin, 1981; Bono, 1976). In
rats CB1O-277 was activated more readily than dacarbazine
(Rutty et al., 1986). Structural similarities, improved in vitro
stability and the possibility of improved metabolic activation
stimulated interest to develop CBIO-277 as a possible
anticancer agent.
Toxicological studies were performed on behalf of the
Cancer Research Campaign by the British Industrial Bio-
logical Research Association (BIBRA). Mice were treated
intravenously with 50-500mgkg-' (150-1500mgm-2) of
CBIO-277 as a single dose dissolved in saline. The LD1O and
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Figure 1 Basic structure of triazenes
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LD50 were 265 mg kg-' (800 mg m-2) and 343 mg kg-'
(1030 mgM-2), respectively. The dose limiting toxicity was
myelosuppression (BIBRA, 1988). Other findings were weight
loss, mottled liver (with elevated transaminases at high
doses), conjunctivitis, piloerection and alopecia. In the pres-
ent study, we compared dacarbazine and CB1O-277 in pre-
clinical tumour models before starting the Phase I trial of
CBIO-277. CBIO-277 pharmacokinetics were studied in mice
and patients for interspecies comparisons of parent drug
clearance and metabolism. This is a report of our preclinical
studies and Phase I trial with pharmacokinetics of CBIO-277
given by intermittent short infusion.
Materials and methods
Drugs and reagents
Dacarbazine was obtained in vials containing 100 mg of
sterile powder from Bayer UK Ltd., Newbury, Berkshire.
The sodium salt of CB1O-277 (molecular weight 215) was
supplied in vials containing 200 mg as a lyophilised, pyrogen
and preservative-free powder by the Development Therapeu-
tics Program, National Cancer Institute, Bethesda, Maryland.
The monomethyl metabolite of CBIO-277 was synthesised as
the potassium salt by Professor Nisi, Instituto di Chemica
Farmaceuticia, University of Trieste, Trieste, Italy, and pro-
vide as a generous gift by Dr Maurizio D'Incalci, Mario
Negri Institute, Milan, Italy.
All chemicals and solvents were either analytical reagent
grade or HPLC grade. Ammonium acetate was obtained
from BDH Chemicals Ltd., Poole, England. Methanol was
obtained from James Burrough, Ltd., Witham, England.
Preclinical studies
Antitumour activity
Xenografts The HX 47 human melanoma xenograft was
established by Selby et al., as previously described (Selby et
al., 1980). The PXN/24 human melanoma xenograft was
established in female random bred athymic nude (Nu/Nu)
mice (Laboratory Animal Center, Carshalton, England) from
the biopsy of a metastatic melanoma nodule. The patient was
chemotherapy-naive at the time of biopsy. Subsequent pas-
sages of this tumour were carried in female Nu/Nu mice
using subcutaneous implants of 2 mm3 fragments. Treatment
was started when the tumours reached 6 mm in one diameter.
The mice were randomised into a control group (five mice
each). The treatment groups received either dacarbazine or
CB1O-277 at 40 mg kg-' (approximately 120mgm2) intra-
peritoneally daily for 5 consecutive days. This dose of CB10-
277 and dacarbazine was equitoxic as measured by whole
body weight loss. Treatment was for four courses over an 8
week period commencing on days 0, 14, 28 and 42 (DO =
initial day of intraperitoneal treatment). Both drugs were
prepared in arachis oil with 10% acetone. Weekly tumour
measurements were recorded for each mouse. Tumour
volume was calculated by the equation (x/6) A x B2, where
A = the largest diameter and B = the diameter at right angle
to A (Morrison, 1983). Group mean values were obtained
and the relative values for treated (T) and control (C) groups
expressed as a percentage (T/C).
Rodent tumours The rodent tumour models described in
Table I were used (Audette et al., 1973; Potter & Robertson,
1960; Rosenoer et al., 1966). Animals were inoculated with
the appropriate tumour fragments or cell suspensions on day
zero of (DO) each experiment. Intraperitoneal treatment with
dacarbazine or CB1O-277 was begun at the specified times
following tumour inoculation and continued for 5 consec-
utive days. Each experiment consisted of 3-9 dose levels as
well as a nontreated control group. Dose levels were deter-
mined by 2-fold escalations from the lowest dose. The drugs
were diluted for injection with either water, saline or 10%
acetone in arachis oil. The activity against the ADJ/PC6
plasmacytoma and Walker 256 mammary carcinosarcoma
were assessed by determining the drug dose that inhibited
tumour growth by 90% (ED 90). The TLX/5 lymphoma and
L1210 lymphocytic leukaemia were assessed by determining
the percentage increase in survival (% ILS).
Pharmacokinetics
Balb c mice were treated with 250 mg kg-' (approximately
750 mgM-2) CB1O-277 reconstituted with normal saline and
injected into a tail vein. Mice were anesthetised with diethyl
ether at 5, 10, 15, 30, 60, 120, 240, 480 and 1440 min
following CBIO-277 injection then plasma samples prepared
from intracardiac blood collected in iced heparinised tubes.
Samples were obtained from four mice per time point. The
iced plasma samples were diluted 1:2 (v/v) in chilled metha-
nol, then centrifuged at 1500g, 0°C for 10min. Standard
curves in chilled mouse plasma of CB1O-277 and the mono-
methyl metabolite were analysed prior to the plasma samples.
Methanolic supernatants of mouse plasma were analysed by
high performance liquid chromatography (HPLC). The
method used was as follows: a 15 x 0.46 cm C8 Spherisorb
analytical column was fitted with a CO:PELL ODS 5 x 0.21
cm precolumn. The methanolic supernatants were kept at
0°C prior to injection onto the analytical column to pro-
tect the heat labile monomethyl species. The mobile phase
was 15% methanol/85% 0.05 M ammonium acetate (v/v).
The flow rate was 1.5 ml min-'. Absorbance was recorded at
280 and 313 nm for 30 min per sample. Results from each
plasma time point were reported as mean ± standard devia-
tion (s.d.). The lower limits of detection were 2 JIM for CBO0-
277 and 1 gIM for the monomethyl metabolite. Area under
plasma concentration x time curve (AUC) values were calcu-
a
b[
0 CH3
R-N- N-N N..
CH20H
I
C364 B.J. FOSTER et al.
Table I Summary of tumour models used in preclinical antitumour tests
Animalsper group Post inoculationa
Tumour Host Inoculation Control each dose First treatment Endpoint
Melanoma xenografts
HX 47 Athymic 2 mm3 5 5 >35 days tumour volumeb
Nude fragments % T/C
Mice
PXN/24 as above ---------------------------------------------------------------------------------------------------------------->
Mouse tumours
ADJ/PC6 Balb (c) 1 mm3 fragments 5-10 3 D20-24 ED 90c
TLX/5 CBA/LAC 105 cells 10 5 D3 % ILSd
L1210 CD2F1 105 cells 10 5 DI % ILS
Rat tumours
Walker Chester 2-6mm3 6 3 DI ED 90
256 Beatty fragments
aInoculation day = day zero (DO) for mouse and rat tumours. tTumour volume % T/C = mean percentage
tumour volume change in treated animals vs nontreated controls. CED 90 = dose that inhibited tumourgrowth by
90%, determined from graph ofdrug dose vs mean percentage tumour weight in treated animals per nontreated
controls (tumourweight %T/C)onloglinearscale; tumourswere removedandweighed 5daysafterlast treatment
(ADJ/PC6) or 3 days after last treatment (Walker 256). d% ILS = maximum mean percentage increase in survival
timeperdosefortreated animals vsnontreatedcontrols; thedose thatproduced themaximum % ILSwasrecorded
for each experiment.
lated by the trapezoidal rule for the monomethyl metabolite
and by integration of the least square fit of a monoexponen-
tial equation for CB1O-277.
Clinical studies
Patient eligibility and evaluation
All patients had metastatic disease either refractory to stan-
dard conventional treatment or for which no standard con-
ventional treatment exists. Performance status of better than
or equal to two by World Health Organization (WHO)
criteria was required (WHO, 1979). Adequate haematologic
studies (haemoglobin O10.0 g dl', leucocyte count >3.0 x
109 -', platelets > 100 x I09 1' -), normal renal (serum urea
and creatinine) and hepatic (serum liver enzymes, and bili-
rubin unless related to liver involvement with metastatic
disease) function were required. A baseline physical examina-
tion, chest X-ray as well as other radiological studies to
document extent of diseases were required within 1 week of
entering the study. Informed consent was obtained following
the guidelines of the local Ethical Committee and the
London Royal College of Physicians.
Weekly follow-up with physical examination, blood or
serum studies to evaluate for possible bone marrow, renal
and hepatic toxicity were performed. Repeat of previously
positive radiological studies were performed every 6-9 weeks
or sooner when indicated. Response and toxicity were graded
by standard WHO criteria (WHO, 1979).
Phase I treatment
The starting dose was 80 mg m2 (1/10 the mouse LDIO).
CB1O-277 was reconstituted in normal saline to give a 50 mg
ml-' solution. Therefore, as the dose was escalated the solu-
tion volume increased. At the dose of 2,000 mg m-2 and
above the infusion time became >O min with the longest
infusion time being 35 min. Treatment was repeated every 21
days. Eleven escalations were used to reach the maximum
tolerated dose (MTD) 6,000 mg m-2. A geometric dose esca-
lation scheme was used to 600 mg m-2 when it became
obvious that the toxic effects per unit dose in patients were
less than those in mice. Thereafter, escalations of 30-50%
over the previous level were used until WHO grade 3 toxicity
that precluded further escalation was observed in 2/3 of
patients treated with the same dose. Intrapatient escalations
were allowed. Patients received two or more courses unless
obvious progressive disease was present after the first course.
Pharmacokinetics
Plasma samples were obtained from heparinised blood kept
at 0°C and taken at 5, 10, 15, 30, 60, 120, 240, 480, 720 and
1080 min after completion of the short infusion. Plasma
samples were prepared for HPLC analysis as described above
for mouse plasma. Standard curves of CBIO-277 and the
monomethyl species in human plasma were analysed with
each set of patient's samples. The CBIO-277 AUC values
were calculated by integration of the least square fit of a
monoexponential equation for patients treated with infusion
of >O min (with correction for infusion time), and a bi-
exponential equation for patients treated with infusions of
< 10 min. AUC values for the monomethyl species were
calculated using the trapezoidal rule.
Results
Preclinical
Antitumour activity Comparative results from the preclinical
antitumour studies are summarised in Table II. The whole
mouse body weight differences in the drug treated groups
(start of treatment - end of the treatment) did not differ
from the nontreated control by >10%. The activity levels of
CBIO-277 and dacarbazine showed variations between
models, e.g. Hx 47 and PXN/24 human melanoma xenografts
tumour volume % T/C was 3 and 8 vs 135 and 71 respective-
ly; ADJ/PC6 plasmacytoma and Walker 256 ED 90 of 2-11
vs 52-64 mg kg-', respectively. However, the activity levels
of the two compounds were similar within each rodent
model, e.g. against TLX/5 CBIO-277 produced % ILS of
72 ± 11 with the optimal dose range being 25-100 mg kg-I
while dacarbazine produced % ILS of 81 ± 17 with the
optimal dose range being 12.5-50 mg kg-'. Although the
CBIO-277 result in the L1210 model (% ILS 37, optimal dose
100 mg kg-') was double the result observed with dacar-
bazine (% ILS 18, same optimal dose) these were from one
experiment and represents activity of little significance in
either case.
Pharmacokinetics The plasma levels of CBIO-277 and its
monomethyl metabolite in mice are shown in Figure 3. All
mouse plasma samples had detectable levels of CBIO-277 up
to and including 120 min. At 240 min three out of four
samples had detectable levels, but the time points after
240 min had levels inconsistently detected. The latter time
points were not included in the pharmacokinetic analysis dueCB1O-277 SHORT INFUSION STUDIES 365
Table II Antitumour results in various rodent models using daily x 5 treatment
Dose or range
Tumour Drug mgkg Levels Resultsa
HX 47 CBIO-277 40 1 3
Dacarbazine 40 1 8
PXN/24 CB1O-277 40 1 135
Dacarbazine 40 1 71
ED 90
mgkg
ADJ/PC6 CBIO-277 0.8-200 6-9 5, 3, 11
Dacarbazine 0.8-200 6-9 5, 2, 4
Walker 256 CD1O-277 12.5-400 6 52, 64
Dacarbazine 12.5-200 5 60
% ILS
TLX/5 CB1O-277 12.5-400 6 56, 70, 72, 80, 83
[optimal dose range = 12.5-00mgkg-']
Dacarbazine 12.5-400 6 59, 82, 84, 100
[optimal dose range = 12.5-50 mg kg-']
L1210 CB1O-277 12.5-400 6 37
[optimal dose = 100 mg kg-']
Dacarbazine 50-200 3 18
[optimal dose = 100 mg kg-']
Active= % ILS ) 20 for TLX/5; > 25 for L1210. aEach value is the result from a
separate experiment.
Table III CBIO-277 patient characteristics
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Figure 3 Plasma levels of CB10-277 (0) and its monomethyl
metabolite (0) in Balb c mice following intravenous treatment
with 250 mg kg-' (750 mg m-2) CB1O-277.
to the variability of detectable drug levels. The CB10-277
peak level was 2723 ± 54ILM and AUC was 142 mM x
minutes at 250 mg kg-'. There was evident of extensive drug
metabolism of the HPLC detection of metabolites in samples
taken from 5 min to 24 h after treatment. The metabolite
identified as the monomethyl derivative of CB10-277 was
detected from 5-120 min. The peak level was 97 ± 23 JLM
detected at 10 min and the AUC for the monomethyl meta-
bolite was 8 mM x minutes.
Clinical
Phase I trial Thirty-six patients (12 females, 24 males)
entered the study and received a total of 80 courses. Details
of patient characteristics are shown in Table III. There were
two early deaths and two patients lost to follow-up. The
median age was 44 years (range 25-71 years). Four patients
(included in this analysis) were ineligible due to performance
status worse than two. Dacarbazine was used as part of the
prior treatment in seven of the patients with melanoma but
none of the patients with sarcomas.
CB10-277 related nausea and vomiting occurred in 45 of
the 57 evaluable courses
g 900 mg m-2 and became dose
limiting at 6,000 mg m-2, Table IV. The routine use of stan-
Total number of patients entered
Number of courses administered
Number of courses fully evaluated
Pharmacokinetics
Patients lost to follow-up or early death
Females
Males
Median age (25-71 years)
Performance status (WHO)
0-1
2
3
Diagnosis: Melanoma
Sarcoma
Non small cell lung
Other
36
80
76
46
4
12
24
44
19
13
4
11
7
4
14
Table IV CB1O-277 toxicity: nausea and vomiting
Dose New Evaluable WHO grade
(mgm-2) patient? courses 0 1 2 3 4
<900 7 15 15 0 0 0 0
900 3 2 2 1 2 0 0
1350 2 6 1 0 2 3 0
2000 4 9 3 0 0 6 0
2800 6 10 3 1 1 5 0
3600 6 13 1 0 0 11 1
4700 5 7 0 0 0 7 0
6000 3 7 0 0 0 7 0
aPatients not previously treated with CB1O-277.
dard antiemetics (which included metochlopramide or
prochlorperazine with and without lorazepam and dexa-
methazone) became increasingly necessary (all courses at
4,700 and 6,000mgm-2). Thus, for some courses associated
with WHO grade 3 nausea and vomiting this toxicity was
manageable. (Note: WHO grade 3 = vomiting requiring
therapy). However at the highest dose the severity of the
nausea and vomiting precluded further dose escalation des-
pite use of antiemetics. Other toxicities are shown in Table V.
Although a warm sensation with or without flushing occur-
red in over 75% of the evaluable courses < 1,350 mg m-2,
this was not associated with blood pressure, pulse or temper-
ature changes and resolved within 30 min of completing the
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Table V CB1O-277 toxicities: other
(76 Evaluable courses)
Flushing or warm sensation nearly all after
1350mgm-2
Diarrhoea Grade 1 7
Perspiration 4
Altered taste 4
Abdominal pain/discomfort 3
Malaise Grade 2 2
Visual changes 2
Rash Grade 1 I
Grade 2 or 3 2
infusion. The other toxicities occurred in less than 10% of
the evaluable courses per category.
Evidence of antitumour activity was observed in six
patients (one complete, two partial, one mixed response in 11
patients with metastatic melanoma; one mixed response in six
patients with sarcomas; one partial response in the patient
with carcinoid). The patient with carcinoid began treatment
with steroids simultaneously with starting CB10-277. Another
patient with metastatic melanoma died suddenly 3 days after
treatment with 6,000 mg m-2. Autopsy revealed cause of
death to be a massive pulmonary embolus, but the sites of
pulmonary metastatic disease were completely necrotic.
Details of the melanoma and sarcoma patients' disease char-
acteristics, prior dacarbazine treatment, CB10-277 doses and
response are summarized in Table VI. The partial or com-
plete responses that occurred in patients with metastatic
melanoma had disease limited to skin or lymph nodes at the
time of treatment. Patient 'A' had no evidence of peripheral
disease when he died of central nervous system metastases
which became evident after starting CB10-277. Patient 'I' had
a complete response 2 months after starting treatment and
has remained in remission for 6 months off CB10-277. The
patient 'P' with sarcoma had exploratory surgery 6 months
after starting treatment. The pelvic mass had clinically
resolved and was not surgically detectable, but the pulmon-
ary lesions had increased in size and were histologically
diagnosed as sarcoma. Response durations have been 6
months or less except for patient 'I'.
Pharmacokinetics
Pharmacokinetics were performed in 46 courses. The AUC of
CB10-277 increased with dose as shown in Figure 4 (linear
regression correlation coefficient = 0.9203, P<0.0001). The
monomethyl species was detected in plasma of some patients
treated with
g
900 mg m-2. Two of the seven patients treated
at the MTD (6,000 mg m-2) were studied and their peak
monomethyl metabolite plasma levels were 18 and 32 M.
These levels were the highest detected in all the patients. The
monomethyl metabolite AUC was 1.8 mM x minutes for the
first patient and 3.7 mM x minutes for the second patient.
Again, these represented the highest values observed. The
plasma levels of CB10-277 and its monomethyl metabolite in
these two patients treated with 6,000 mgm2 are shown in
Figure 5.
Discussion
The need for improved treatment in patients with dacar-
bazine sensitive tumours, particularly malignant melanoma is
generally accepted (Mastrangelo et al., 1985). Even adjuvant
treatment of patients with stage I melanoma has been disap-
pointing with currently available drugs and showed no
improvement in survial for the treated vs nontreated controls
(Veronesi et al., 1982; Tranum et al., 1987). Never the less,
dacarbazine has reproducible antitumour activity in patients
with cutaneous melanoma and for an individual patient the
Table VI Melanoma and sarcoma patients' disease, treatment and response characteristics
Prior dacarbazine CBJO-277
Patient LD. Diagnosis Disease sites combination dosemgm-2 Response
A Melamona Skin yes 264-900 partial
Lymph nodes [duration 2 months]
B Melanoma Skin yes 400-600 mixed
[duration 2 months]
C Melanoma Skin yes 600 disease progression
Lymph nodes
D Melanoma Skin no 2000 partial
Lymph nodes [duration 1 month]
E Melanoma Liver yes 3600 disease progression
F Melanoma Skin yes 3600 disease progression
Lungs
Liver
G Melanoma Skin yes 3600 disease progression
Lungs
Bones
H Melanoma Lymph nodes yes 4700 disease progression
Lungs
I Melanoma Lymph nodes no 6000 complete
[duration > 10
months]
J Melanoma Lymph nodes yes 6000 disease progression
K Melanoma Lungs no 6000 necrotic tumour in
Liver lungs at autopsy
L Sarcoma Muscle mass no 160-264 disease progression
Lungs
Bones
M Sarcoma Abdominal mass no 900-1350 disease progression
N Sarcoma Muscle mass no 900-1350 disease progression
Lungs
0 Sarcoma Liver no 2000-2800 disease progression
P Sarcoma Pelvic mass no 2800 mixed
Lungs [duration 6 months]
Q Sarcoma Muscle mass no 4700 disease progression
Lungs
R Sarcoma Abdominal masses no 6000 disease progressionCB1O-277 SHORT INFUSION STUDIES 367
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Figure 4 Area under the CB1O-277 concentration x time curve
(AUC) vs dose in patients treated on intravenous short infusion
trial of CB1O-277.
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Figure 5 Plasma levels of CB1O-277 (closed symbols) and its
monomethyl metabolite (open symbols) in patients (S.M. A A,
L.P. 0) treated at the maximum tolerated dose
(6000 mg mi2).
response (complete or partial) can be meaningful with dura-
tions sometimes greater than 12 months (Comis, 1976).
Dacarbazine is an imidazole dimethyltriazene that is poor-
ly soluble and unstable in aqueous solution at physiologic
pH. It requires metabolic activation with formation of a
monomethyl triazene for anti-tumour activity (Audette et al.,
1973; Gescher et al., 1981). Although the ability to form a
monomethyl species is required for antitumour activity, this
may not be the sole mechanism by which triazenes exert their
in vivo antitumour activity (Gescher et al., 1981; Sava et al.,
1988). Some Mer- cells are relatively sensitive to the
monomethyl species of dacarbazine in vitro, but it is unclear
whether this phenotype is a direct or indirect determinant of
the lethal effects of triazenes (Gibson et al., 1986; Lunn &
Harris, 1988). However, even if monomethyl metabolite for-
mation is not the sole determinant of activity, a higher level
might be expected to be associated with improved activity.
Numerous compounds with structural similarities to dacar-
bazine that have preclinical activity exist (Loo & Lin, 1972;
Audette et al., 1973; Connors et al., 1976; Loo et al., 1976;
Giraldi et al., 1977; Hatheway et al., 1978; Wilman & God-
dard, 1980; Gescher et al., 1981; Shealy & Krauth, 1966;
Vaughn et al., 1984). CB10-277, a phenyl dimethyltriazene, is
soluble and stable in aqueous solutions at physiologic pH
(Wilman & Goddard, 1980). The level of formation of the
monomethyl species from CB10-277 and from dacarbazine
was similar in mice, but the levels of the monomethyl formed
from CB10-277 was higher in rats when compared to those
formed from dacarbazine (Rutty et al., 1986). In our pre-
clinical models, CB10-277 demonstrated comparable anti-
tumour activity to dacarbazine on a multiple dose schedule.
Similar results in other models have been reported by other
investigators, who also noted no significant difference in
haematologic toxicity (Colombo & D'Incalci, 1984). Thus,
the preclinical antitumour results support the hypothesis that
the antitumour activity ofCB10-277 and dacarbazine are at
the very least similar. Additional studies comparing a single
dose of dacarbazine with daily x 5 treatment in the ADJ/
PC6 and Walker 256 models showed similar antitumour
activity when total mg kg-' doses were compared (C.J.
Rutty, unpublished data). However, toxicity as measured by
the LD50 was more with the single dose schedule. We chose
a single dose schedule for the initial CB10-277 Phase I study
because of the simplicity and reduced cost in patient and staff
resources of this schedule compared to others. In addition,
since toxicity and antitumour activity are Phase I endpoints;
we felt that if activity was observed on the simplest schedule,
more costly or complicated dose schedule(s) could be per-
formed after the initial study results were available.
Species differences in parent drug and monomethyl meta-
bolite levels were observed between mice and patients. The
parent drug AUC in mice treated with 250 mg kg-' (750 mg
m-2) was 142 M x minutes; while in patients treated with
600 and 900mgm-2 it was 48 ± 13 and 60 ± 16mMx
minutes (mean ± s.d.), respectively. Correspondingly, the
monomethyl metabolite AUC in mice treated with 750 mg
m 2 was 8 mM x minutes; but even at the MTD in patients
(6,000mgm-2) the highest monomethyl AUC was 3.7 mM x
minutes. Although the parent drug AUC in patients treated
at the MTD (mean 559mM x minutes) exceeded the parent
drug AUC in mice treated with 750mg m-2 (142 mM x
minutes), the monomethyl metabolite AUC in patients at the
MTD was less than predicted, based on levels in mice.
Therefore, although qualitative species similarities in CB10-
277 metabolism in mice and patients were detected, clear
quantitative differences exist. Not only do patients have a
higher plasma clearance of the parent compound, they are
less efficient in forming the monomethyl metabolite. Despite
the monomethyl levels in patients being less than expected,
based on the predictions from mice studies, they were more
than double levels that have been shown to produce in vitro
cytotoxicity with similar monomethyl triazenes (Gibson et
al., 1986; Gibson et al., 1986a).
As with dacarbazine, nausea and vomiting were dose limit-
ing. Except for the flushing sensation, which was short lived
and self limiting, other toxicities were infrequent. Of partic-
ular interest was that no evidence of myelosuppression or
liver function abnormalities were observed with administra-
tion of CB10-277 by short infusion. There were one complete
and two partial responses in patients with metastatic mela-
noma. One patient with recurrent carcinoid also had a partial
response. Additional evidence of antitumour activity (mixed
responses, tumour necrosis at autopsy) occurred in patients
with melanoma and sarcoma. Athough the responses occur-
red in patients who arguably might have responded to dacar-
bazine and occurred in subcutaneous, nodal or lung disease;
the patients were not required to remain in the hospital for
treatment nor return daily for 5 days. In addition, the nausea
and vomiting, even in patients with the most severe symp-
toms, resolved by 24 h.
An additional Phase I study of CB10-277 using a 24 h
continuous infusion was performed to investigate whether the
severity of the acute nausea and vomiting could be reduced.
Details of the 24 h continuous infusion study and further
discussion of the rationale are given in the accompanying
manuscript. The usefulness of CB10-277 in dacarbazine sen-
sitive histologies can best be determined by a randomised
comparison of the two drugs. The dose and schedule of
CB10-277 recommended for future studies is given and dis-
cussed in the 24 h continuous infusion manuscript.
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